This is a phase III, eighteen month study to assess the efficacy and safety of Brolucizumab versus Aflibercept in patients with macular oedema that is secondary to a central retinal vein occlusion.
Participants need to be treatment naïve, and have had a central retinal vein occlusion for less than 6 months.
Please contact the Clinical Trials Office on (08) 9381 0750 or email clinicalresearch@lei.org.au
Trial registry number: EUDRACT number 2018-001788-21.
